Spyre Therapeutics, Inc.

As of October 24, 2025, Spyre Therapeutics, Inc. shows a bullish technical trend with strong weekly indicators, though mixed signals on monthly performance, having outperformed the S&P 500 recently but lagging behind year-to-date and one-year returns.

As of October 24, 2025, Spyre Therapeutics, Inc. has a bullish technical trend with strong short-term momentum, having outperformed the S&P 500 recently, despite underperforming over the longer term.

As of September 8, 2025, Spyre Therapeutics, Inc. is in a mildly bearish trend, supported by bearish daily moving averages and Bollinger Bands, with a year-to-date return of -34.19%, significantly underperforming the S&P 500's 12.22%.

As of February 29, 2024, Spyre Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics, including a Price to Book Value of 2.12, an EV to EBIT of -2.14, and a Return on Equity of -33.70%, alongside poor stock performance and unfavorable comparisons to its peers.

As of June 17, 2025, Spyre Therapeutics, Inc. is in a mildly bearish trend, supported by bearish daily moving averages and Bollinger Bands, with mixed signals from MACD and KST indicators.

As of March 2022, the management team of Spyre Therapeutics, Inc. includes Mr. Russell Cox (Independent Chairman), Dr. Anthony Quinn (President and CEO), and several independent directors: Ms. Alison Lawton, Dr. Suzanne Bruhn, Dr. V. Bryan Lawlis, Dr. Ivana Magovcevic-Liebisch, and Mr. Sandesh Mahatme. This team combines executive leadership with independent oversight.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing enzyme therapeutics for rare diseases, with a market cap of approximately $916.17 million and a recent net profit of -$36 million. The company is classified as a micro-cap and has no dividend yield.

As of Jun 18, Spyre Therapeutics, Inc. has a market capitalization of 916.17 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -160.22 million over the latest four quarters.